Factors affecting levodopa effects in Parkinson's disease

Acta Medica Okayama

Volumn 54, Issue 3, 2000, Pages 95-101

  Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Age at onset; Blood brain barrier; Catechol O methyltransferase (COMT) inhibitor; Dopamine agonist; Gastric acidity; Large neutral amino acids; Monoamine oxidase B (MAO B) inhibitor

Indexed keywords

ANTIPARKINSON AGENT; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; ENZYME INHIBITOR; LEVODOPA;

ABSORPTION; BLOOD BRAIN BARRIER; DRUG ANTAGONISM; METABOLISM; PARKINSON DISEASE; REVIEW;

ABSORPTION; ANTIPARKINSON AGENTS; BLOOD-BRAIN BARRIER; DOPA DECARBOXYLASE; DOPAMINE; ENZYME INHIBITORS; LEVODOPA; PARKINSON DISEASE;

EID: 0034199085     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Chase TN, Mouradian MM and Engber TM: Motor response complications and the function of striatal efferent systems. Neurology (1993) 43, S23-S27.
2. Fahn S: Controversies in the therapy of Parkinson's disease. Adv Neurol (1996) 69, 477-486.
3. Marsden CD and Parkes JD: "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 1, 292-296.
4. Lieberman A, Estey E, Gopinathan G, Ohashi T, Sauter A and Goldstein M: Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease. Neurology (1978) 28, 964-968.
5. Pakkenberg H, Birket-Smith E, Dupont E, Hansen E, Mikkelsen B, Presthus J, Rautakorpi I, Riman E and Rinne UK: Parkinson's disease treated with Sinemet or Madopar: A controlled multicenter trial. Acta Neurol Scand (1976) 53, 376-385.
6. Inoue N and Miyoshi S: Amelioration of wearing-off phenomenon by exchanging of levodopa-DCI drugs. Neurol Med (Tokyo) (1994) 40, 313. (Japanese)
7. Metman LV, Hoff J, Mouradian MM and Chase TN: Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/ carbidopa. Mov Disord (1994) 9, 463-465.
8. Pappert EJ, Goetz CG, Niederman F, Ling ZD, Stebbins GT and Carvey PM: Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology (1996) 47, 1493-1495.
9. Wade DN, Mearrick PT and Morris JL: Active transport of L-dopa in the intestine. Nature (1973) 242, 463-465.
10. Mearrick PT, Wade DN, Birkett DJ and Morris J: Metoclopramide, gastric emptying and L-dopa absorption. Aust N Z J Med (1974) 4, 144-148.
11. Djaldetti R, Koren M, Ziv I, Achiron A and Melamed E: Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord (1995) 10, 81-84.
12. Neira WD, Sanchez V, Mena MA and de-Yebenes JG: The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord (1995) 10, 66-70.
13. Indo T and Ando K: Metoclopramide-induced Parkinsonism: Clinical characteristics on ten cases. Arch Neurol (1982) 39, 494-496.
14. Champion MC: Domperidone. Gen Pharmacol (1988) 19, 499-505.
15. Yazawa I, Terao Y, Sai I, Hashimoto K and Sakuta M: Gastric acid secretion and absorption of levodopa in patients with Parkinson's disease: The effect of supplement therapy to gastric acid. Clin Neurol (Tokyo) (1994) 34, 264-266. (Japanese with English Abstract)
16. Mena I and Cotzias GC: Protein intake and treatment of Parkinson's disease with levodopa. N Engl J Med (1975) 292, 181-184.
17. Riley D and Lang AE: Practical application of a low-protein diet for Parkinson's disease. Neurology (1988) 38, 1026-1031.
18. Juncos JL, Fabbrini G, Mouradian MM, Serrati C and Chase TN: Dietary influences on the antiparkinsonian response to levodopa. Arch Neurol (1987) 44, 1003-1005.
19. Kurlan R: Dietary therapy for motor fluctuations in Parkinson's disease. Arch Neurol (1987) 44, 1119-1121.
20. Pincus JH and Barry K: Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology (1988) 38, 481-483.
21. Berry EM, Growdon JH, Wurtman JJ, Caballero B and Wurtman RJ: A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology (1991) 41, 1295-1297.
22. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, Nahmias C, Jones T and Marsden CD: Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 49, 853-860.
23. Tsui JK, Ross S, Poulin K, Douglas J, Postnikoff D, Calne S, Woodward W and Calne DB: The effect of dietary protein on the efficacy of L-dopa: A double-blind study. Neurology (1989) 39, 549-552.
24. Nutt JG, Woodward WR, Hammerstad JP, Carter JH and Anderson JL: The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med (1984) 310, 483-488.
25. Baruzzi A, Contin M, Riva R, Procaccianti G, Albani F, Tonello C, Zoni E and Martinelli P: Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol (1987) 10, 527-537.
26. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E and Chase TN: Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part I. Ann Neurol (1988) 24, 366-371.
27. Nutt JG, Woodward WR, Gancher ST and Merrick D: 3-O-methyldopa and the response to levodopa in Parkinson's disease. Ann Neurol (1987) 21, 584-588.
28. Guttman M, Leger G, Cedarbaum JM, Reches A, Woodward W, Evans A, Diksic M and Gjedde A: 3-O-Methyldopa administration does not alter fluorodopa transport into brain. Ann Neurol (1992) 31, 638-643.
29. Schuh LA and Bennett JP Jr: Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology (1993) 43, 1545-1550.
30. Alexander GM, Schwartzman RJ, Grothusen JR and Gordon SW: Effects of plasma levels of large neutral amino acids and degree of parkinsonism on the blood-to-brain transport of levodopa in naive and MPTP parkinsonian monkeys. Neurology (1994) 44, 1491-1499.
31. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM and Chase TN: Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology (1993) 43, 2685-2688.
32. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE and Yoo K: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology (1997) 48, 81-87.
33. Kaakkola S, Teravainen H, Ahtila S, Rita H and Gordin A: Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology (1994) 44, 77-80.
34. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP and Gordin A: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 44, 913-919.
35. Ahtila S, Kaakkola S, Gordin A, Korpela K, Heinavaara S, Karlsson M, Wikberg T, Toumainen P and Mannisto PT: Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol (1995) 18, 46-57.
36. The Parkinson Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med (1993) 328, 176-183.
37. Heikkila RE, Cabbat FS, Manzino L and Duvoisin RC: Potentiation by deprenil of l-dopa induced circuling in nigral-lesioned rats. Pharmacol Biochem Behav (1981) 15, 75-79.
38. Riederer P and Youdim MB: Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with I-deprenyl. J Neurochem (1986) 46, 1359-1365.
39. LeWitt RA: Levodopa therapeutics: New treatment strategies. Neurology (1993) 43, S31-S37.
40. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ and Chase TN: Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, Part II. Ann Neurol (1988) 24, 372-378.
41. Seeman P and Niznik HB: Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J (1990) 4, 2737-2744.
42. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P and Anliker M: T2 relaxation time in patients with Parkinson's disease. Neurology (1993) 43, 697-700.
43. 11C-raclopride and positron emission tomography. Ann Neurol (1992) 31, 184-92.
44. Brucke T, Wenger S, Asenbaum S, Fertl E, Pfafflmeyer N, Muller C, Podreka I and Angelberger P: Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol (1993) 60, 494-500.
45. 123IIBZM-SPECT. Mov Disord (1993) 8, 453-458.
46. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL and Mouradian MM: Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology (1989) 39, S7-S10.
47. Ogawa N: Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med Okayama (1995) 49, 1-11.
48. Ahlskog JE, Muenter MD, Bailey PA and Stevens PM: Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide). Arch Neurol (1992) 49, 560-568.
49. Robertson HA, Peterson MR and Worth GG: Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243. Brain Res (1992) 593, 332-334.
50. Ogawa N: Levodopa and dopamine agonists in the treatment of Parkinson's disease: Advantages and disadvantages. Eur Neurol (1994) 34, S20-S28.
51. Bonuccelli U, Piccini P, DelDotto P, Rossi G, Corsini GU and Muratorio A: Apomorphine test for dopaminergic responsiveness: A dose assesment study. Mov Disord (1993) 8, 158-164.
52. Cedarbaum JM: Pharmacokinetic and pharmacodynamic considerations in manegement of motor response fluctuations in Parkinson's disease. Neurol Clinics (1990) 8, 31-49.
53. Nutt JG, Carter JH, Woodward W, Hammerstad JP and Gancher ST: Dose tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions. Mov Disord (1993) 8, 139-143.
54. Febbrini G, Juncos JL, Mouradian MM, Serrati C and Chase TN: 3-O-methyldopa and motor fluctuations in Parkinson's disease. Neurology (1987) 37, 856-859.
55. Murata M and Kanazawa I: Repeated L-dopa administration reduces the ability of dopamine storage and abolishes the supersensitivity of dopamine receptors in the striatum of intact rat. Neurosci Res (1993) 16, 15-23.
56. Bravi D, Mouradiam MM, Roberts JW, Davis TL, Sohn YH and Chase TN: Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms. Ann Neurol (1994) 36, 27-31.
57. Murata M, Mizusawa H, Yamanouchi H and Kanazawa I: Chronic levodopa therapy enhances dopa absorption: Contribution to wearing-off. J Neural Transm (1996) 103, 1177-1185.
58. Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, Hammerstad J and Calne DB: Clinical observation on the rate of progression of idiopathic parkinsonism. Brain (1994) 117, 501-507.
59. Murata M and Kanazawa I: Effects of chronic levodopa therapy on dopa pharmacokinetics. Eur Neurol (1997) 38, S50-S55.
60. Roos RA, Vredevoogd CB and van der Valde EA: Response fluctuations in Parkinson's disease. Neurology (1990) 40, 1344-1346.
61. Ogawa N, Tanaka K and Asanuma M: Bromocriptine markedly suppress levodpa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem Res (2000) 25, 755-758.